吡非尼酮
DLCO公司
医学
特发性肺纤维化
肺活量
内科学
扩散能力
队列
肺功能测试
任天堂
外科
肺
肺功能
作者
Monika Žůrková,Eva Kriegová,Vı́tězslav Kolek,Vladimíra Lošťáková,Martina Šterclová,Vladimı́r Bartoš,Martina Doubková,Ilona Binková,Michal Svoboda,Jana Strenková,Markéta Janotová,Martina Plačková,Ladislav Lacina,Vladimír Řihák,František Petřík,Pavlína Lisá,Radka Bittenglová,Richard Tyl,Gustáv Ondrejka,Hana Šuldová
标识
DOI:10.1186/s12931-019-0977-2
摘要
Our study observed the 2-yrs sustained effect of pirfenidone on the decline of lung function and survival in the real-world patient's IPF cohort. DLCO decline of ≥10% shows a potential as a mortality predictor in IPF patients on pirfenidone, and should be routinely evaluated during follow-up examinations.
科研通智能强力驱动
Strongly Powered by AbleSci AI